Delivering Integrated Safety and Efficacy Analyses in Cushing Syndrome

1 minute read

Published: October 6th, 2025

When faced with evolving analysis plans, minimal client infrastructure, and shifting output volumes, Phastar delivered high-quality ISS and ISE outputs for Cushing syndrome clinical studies. 

By combining automation, custom macros, and strategic agility within an FSP model, our team adapted quickly to changing sponsor needs—ensuring consistent quality and on-time delivery despite significant mid-project changes. 

This case study demonstrates how innovation, collaboration, and flexibility can transform complex integration challenges into regulatory-ready solutions that add lasting value for the sponsor. 

Complete the form to download the full case study.

Related articles

Delivering a Complex ISS in Autoimmune Pulmonary Alveolar Proteinosis

Delivering a Complex ISS in Autoimmune Pulmonary Alveolar Proteinosis

September 26th, 2025 1 minute read

Phastar supported a sponsor in delivering a high-quality Integrated Summary of Safety (ISS) for a rare disease progra...

Delivering Integrated Efficacy and Safety Summaries in VMS

Delivering Integrated Efficacy and Safety Summaries in VMS

September 26th, 2025 1 minute read

Integrating efficacy and safety data across multiple studies is never simple—especially when patient-reported outcome...

CRO Oversight: Restoring Quality to Outsourced Oncology and Rheumatology Studies

CRO Oversight: Restoring Quality to Outsourced Oncology and Rheumatology Studies

July 16th, 2025 1 minute read

After acquiring a biotech, a global pharma company faced major issues with two ongoing pharmacokinetic studies—both f...